Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility

Clinical and Translational Oncology

Volumn 16, Issue 1, 2014, Pages 107-112

  Cebrian A ^a   Taron, M ^b   Sala, N ^b   Ardanaz, E ^c,d   Chirlaque, M D ^d,e   Larranaga N ^d,f   Redondo, M L ^g   Sanchez M J ^d,h   Gomez Del Pulgar T ^a   Camps, C ^i,j   Rosell, R ^b   Gonzalez C A ^b   Lacal, J C ^a  

^a UAM)   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e Murcia Regional Health Authority   (Spain)

^f BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^g Public Health Directorate Asturias   (Spain)

^h ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^j UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

Case control study; Lung cancer; Phosphatidylcholine pathway; Polymorphism; Rho GTPases; Risk assessment

Indexed keywords

CITICOLINE; PHOSPHOLIPID; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHOSPHOLIPID METABOLISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHOLINE KINASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RHO GTP-BINDING PROTEINS;

EID: 84893775674     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1080-7     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Santos CR, Schulze A. Lipid metabolism in cancer. The FEBS journal. 2012;279:2610-23.
3. Rodriguez-Gonzalez A, Ramirez de Molina A, Benitez-Rajal J, Lacal JC. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003;5:191-201.
4. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007;8:889-97.
5. Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005;65:5647-53.
6. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 2005;27:602-13.
7. Riou P, Villalonga P, Ridley AJ. Rnd proteins: multifunctional regulators of the cytoskeleton and cell cycle progression. BioEssays. 2010;32:986-92.
8. Zhang C, Zhou F, Li N, Shi S, Feng X, Chen Z, et al. Overexpression of RhoE has a prognostic value in non-small cell lung cancer. Ann Surg Oncol. 2007;14:2628-35.
9. Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, et al. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS ONE. 2012;7:e42012.
10. Carman GM, Han GS. Roles of phosphatidate phosphatase enzymes in lipid metabolism. Trends Biochem Sci. 2006;31:694-9.
11. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747-54.
12. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011;103:817-25.
13. Agudo A, Peluso M, Sala N, Capella G, Munnia A, Piro S, et al. Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults: findings from the EPIC-Spain cohort. Carcinogenesis. 2009;30:968-76.
14. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics. 2007;23:644-5.
15. Corrao MA, Guindon GE, Cokkinides V, Sharma N. Building the evidence base for global tobacco control. Bull World Health Organ. 2000;78:884-90.
16. Parkin DM, Pisani P, Lopez AD, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer (J Int du cancer). 1994;59:494-504.
17. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165:1163-71.
18. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36-49.
19. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2007;28:507-18.